The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.
05-Nov-2009 - US R&D facilities in Rahway and Kenilworth, New Jersey will remain operational as they are vital to the to the newly formed Merck Schering-Plough group, according to CEO Richard Clark....
02-Nov-2009 - Lonza cuts 2009 earning guidance and may reduce its workforce under “Project Bond” cost cutting plan after a Q3 characterized by an “accumulation of unexpected events”
22-Oct-2009 - IMS Health has confirmed it is “exploring strategic alternatives” after speculation this week suggested that the market analysis group had received a number of takeover bids.
20-Oct-2009 - Swiss healthcare services giant Lonza has withdrawn its offer for Canadian CMO Patheon, citing value considerations, rejection of the bid by JLL and the availability of alternatives.
20-Oct-2009 - CNS focused drugmaker H Lundbeck says its acquisition of French CMO Elaiapharm represents a cheaper option than third-party manufacturing.
15-Oct-2009 - US drugmaker Eli Lilly will sell its Tippecanoe laboratories API manufacturing unit to Germany’s Evonik Industries.
15-Oct-2009 - Lonza says that to the Indian market was a key motivation for its acquisition of Simbiosys Biowares India preclinical cell and molecular biology assets.
08-Oct-2009 - We look ahead to CPhI 2009 which takes place in Madrid, Spain next week and will showcase the world’s leading ingredients, contract services, machinery and biotech companies.
07-Oct-2009 - MannKind’s share price tumbled by 31 per cent yesterday, just days after it published encouraging safety data for Afresa, because it revealed a partnership deal is unlikely to occur in 2009.
06-Oct-2009 - Despite the government’s “aggressive” promotion of generic drugs, pharmaceutical spending in France will continue to grow, according to new analysis by Business Monitor International (BMI).
06-Oct-2009 - Hospira has acquired the worldwide rights to filgrastim and a Croatian biologics plant from Pliva, increasing its presence in the biogenerics field, and told in-PharmaTechnologist that further expansions are possible.
01-Oct-2009 - Sun Pharmaceuticals says the new lawsuit filed against it by Taro Pharmaceuticals is “another unfortunate attempt by the Taro directors to divert Taro's limited resources to assisting the Levitt family...
29-Sep-2009 - US health care major J&J has paid €302m for an 18 per cent stake in Dutch biotechnology Crucell and announced plans for a collaborative drug development programme.
28-Sep-2009 - Abbott Laboratories will buy Solvay’s pharmaceutical unit for €4.8bn ($7bn) according to reports released earlier today.
28-Sep-2009 - The pharmaceutical division of Indian API maker Camlin Fine chemicals may be put up for sale by its parent company, stationary giant Camlin, after failing to expand.
24-Sep-2009 - The European Commission has approved Novartis’ €925m ($1.2bn) acquisition of Ebewe Spezial-Pharma’s generic injectables business.
10-Sep-2009 - With Lonza and JLL competing over Patheon Outsourcing-Pharma looks at what the CMO offers to a prospective buyer, analysing its global manufacturing capacity and backlog using interactive maps and graphs.
08-Sep-2009 - Pharmaceutical manufacturer Galencia says its acquisition of Switzerland-based biotech group OM Pharma will bolster its international presence.
07-Sep-2009 - Cloud Packaging Solutions has said the acquisition of Toll Packaging will boost its ability to meet the increased demand for shorter packing runs triggered by the current global economic crisis.
03-Sep-2009 - Japanese drugmaker Dainippon Sumitomo Pharma (DSP) has entered into a definitive agreement to acquire US pharmaceutical group Sepracor for $2.6bn (€1.8bn).
02-Sep-2009 - Swiss drug major Novartis will UK specialty pharma firm BTG up to $10m (€7m) for its HySolv drug delivery technology.
31-Aug-2009 - Basel-headquartered Roche has paid fellow Swiss firm Lonza $290m (€203m) for its Singapore biologics plant in a bid to secure long-term manufacturing capacity for biotech cancer drugs.
24-Aug-2009 - Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon...
24-Aug-2009 - Woman’s healthcare and dermatology group Warner Chilcott will unveil plans to buy P&G’s prescription drug division for $3bn (€2.1bn) according to a number of media reports.
17-Aug-2009 - Amcor has temporarily halted trading on the Australian stock exchange, fuelling rumours that the group is finally about to move for Rio Tinto’s Alcan pharmaceutical packaging unit.